We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in...
In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting investors’ caution as they analyze revelations from Nvidia’s artificial intelligence...
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
falseQ30001807120--12-31http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent0001807120dsgn:TwoT...
false000180712000018071202023-11-132023-11-13 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.08 | 36.6101694915 | 2.95 | 4.09 | 2.9109 | 700251 | 3.64320039 | CS |
4 | 1.1 | 37.542662116 | 2.93 | 4.09 | 2.4501 | 311805 | 3.25110868 | CS |
12 | 1.53 | 61.2 | 2.5 | 4.09 | 2.245 | 249887 | 2.82717993 | CS |
26 | 1.56 | 63.1578947368 | 2.47 | 4.09 | 1.96 | 344071 | 2.4761246 | CS |
52 | -1.77 | -30.5172413793 | 5.8 | 8.47 | 1.94 | 471026 | 3.15372941 | CS |
156 | -33.2491 | -89.1896531837 | 37.2791 | 43 | 1.94 | 325817 | 8.9218033 | CS |
260 | -23.97 | -85.6071428571 | 28 | 50 | 1.94 | 326475 | 9.03039759 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions